A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 555-561

  Hecht, J Randolph ^a   Bedford, Rudolph ^a   Abbruzzese, James L ^b   Lahoti, Sandeep ^c   Reid, Tony R ^e   Soetikno, Roy M ^e   Kirn, David H ^d   Freeman, Scott M ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Medical Clinic of Houston   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; GEMCITABINE; ONYX 015;

ADENOVIRUS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; DUODENUM PERFORATION; ENDOSCOPIC ECHOGRAPHY; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; HYPERAMYLASEMIA; HYPERLIPIDEMIA; INOPERABLE CANCER; LEUKOPENIA; LUNG TOXICITY; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; VIRUS REPLICATION;

EID: 0037314610     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal, A., Murray, T., Samuels, S., Ghafoor, A., Ward, E., and Thun, M. Cancer Statistics, 2003. CA Cancer J. Clin., 53: 5-26, 2003.
2. Warshaw, A. L., and Fernandez-del Castillo, C. Pancreatic carcinoma. N. Engl. J. Med., 326: 455-465, 1992.
3. Haskell, C., Lavey, R. S., and Raming, K. P. Exocrine pancreas. In: C. M. Haskell (ed.), Cancer Treatment, 4th ed., pp. 502-512. Philadelphia: W. B. Saunders, 1995.
4. Evans, D. B., Abbruzzese. J. L., and Willett, C. G. Cancer of the pancreas. In: V. D. Vita, Jr., S. Hellman, and S. Rosenberg (eds.), Cancer: Principles and Practice, 6th ed., pp. 1126-1161. Philadelphia: Lippincott Williams & Wilkins, 2001.
5. Moertel, C. G., Frytak, S., Hahn, R. G., O'Connell, M. J., Reitemeier, R. J., Rubin, J., Schutt, A. J., Weiland, L. H., Childs, D. S., Holbrook, M. A., Lavin, P. T., Livstone, E., Spiro, H., Knowlton, A., Kalser, M., Barkin, J., Lessner, H., Mann-Kaplan, R., Ramming, K., Douglas, H. O., Jr., Thomas, P., Nave, H., Bateman, J., Lokich, J., Brooks, J., Chaffey, J., Corson, J. M., Zamcheck, N., and Novak, J. W. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer (Phila.), 48: 1705-1710, 1981.
6. Burris, H. A., III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
7. Kirn, D. H. Replication-selective microbiological agents: fighting cancer with targeted germ warfare. J. Clin. Investig., 105: 837-839, 2000.
8. Kirn, D., Hermiston, T., and McCormick, F. ONYX-015: clinical data are encouraging. Nat. Med., 4: 1341-1342, 1998.
9. Kirn, D. H. A tale of two trials: selectively replicating herpes viruses for brain tumors. Gene Ther., 7: 815-816, 2000.
10. Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., and Martuza, R. L. Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther., 7: 867-874, 2000.
11. Hallenbeck, P. L., Chang, Y. N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., and Chiang, Y. L. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther., 10: 1721-1733, 1999.
12. Norman, K. L., and Lee, P. W. Reovirus as a novel oncolytic agent. J. Clin. Investig., 105: 1035-1038, 2000.
13. Barker, D. D., and Berk, A. J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology, 156: 107-121, 1987.
14. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
15. Harada, J. N., and Berk, A. J. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol., 73: 5333-5344, 1999.
16. Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C., and Kirn, D. H. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res., 60: 1193-1196, 2000.
17. Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., and zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol., 72: 9470-9478, 1998.
18. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
19. Ries, S. J., Brandts, C. H., Chung, A. S., Biederer, C. H., Hann, B. C., Lipner, E. M., McCormick, F., and Korn, W. M. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat. Med., 6: 1128-1133, 2000.
20. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S., and Kirn, D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res., 60: 6359-6366, 2000.
21. Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., Romel, L., Randlev, B., Kaye, S., and Kirn, D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol., 19: 289-298, 2001.
22. Kirn, D. Clinical research results with d11520 (ONYX-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther., 8: 89-98, 2001.
23. Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., and Kirn, D. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther., 8: 308-315, 2001.
24. Heise, C. C., Williams, A., Olesch, J., and Kirn, D. H. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther., 6: 499-504, 1999.
25. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885, 2000.
26. Wiersema, M. J., Vilmann, P., Giovannini, M., Chang, K. J., and Wiersema, L. M. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology, 112: 1087-1095, 1997.
27. Chang, K. J., Nguyen, P. T., Thompson, J. A., Kurosaki, T. T., Casey, L. R., Leung, E. C., and Granger, G. A. Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma. Cancer (Phila.), 88: 1325-1335, 2000.
28. Ganly, I., Eckhardt, S. G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C., Von Hoff, D. D., and Kaye, S. B. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res., 6: 798-806, 2000.
29. Reid, T., Sze, D., Galanis, E., Andrews, J., Abbruzzese, J., Freeman, S., Post, L., and Kirn, D. Intra-arterial administration of a replication-selective adenovirus Onyx-015 in patients with colorectal carcinoma metastastatic to the liver: safety, feasibility, and biological activity. Proc. Am. Assoc. Cancer Res., 43: 858, 2002.
30. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Romel, L., Hatfield, M., Rubin, J., and Kirn, D. Intra-arterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial. Gene Ther., 8: 1618-1626, 2001.
31. Kirn, D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene, 19: 6660-6669, 2000.